Literature DB >> 26617948

Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Yin Li1, Da-Fu Xu2, Dong Jiang3, Jun Zhao3, Jin-Feng Ge3, Shi-Ying Zheng3.   

Abstract

OBJECTIVE: To investigate the relation of Fas and Fas ligand (FasL) protein expression with carcinogenesis and metastasis of cardiac carcinoma.
METHODS: Immunohistochemistry was used to detect Fas and FasL protein expression in 64 cardiac carcinoma tissue samples and 20 normal gastric tissue samples. Relation between FasL and Fas expression, age and gender of gastric cancer patients, and pathological subtype and lymph node metastasis of gastric cancer was analyzed.
RESULTS: The Fas expression level was significantly higher in normal gastric tissue samples than in cardiac carcinoma tissue samples (85.0% vs. 25.0%, P<0.001), while the FasL expression level was significantly lower in normal gastric tissue samples than in cardiac carcinoma tissue samples (30.0% vs. 81.3%, P<0.001). The Fas expression level was significantly higher in invasive lymph nodes than in non-invasive lymph nodes (82.9% vs. 56.5%, P<0.003) and in well-differentiated gastric carcinoma tissue samples than in poorly-differentiated cardiac carcinoma tissue samples (50.0% vs. 18.0%, P=0.015). The FasL expression level was significantly lower in well-differentiated cardiac carcinoma tissue samples than in poorly- differentiated cardiac carcinoma tissue samples (42.9% vs. 84.0%, P=0.021). The Fas and FasL expression levels (25.0% and 81.3%) were significantly different in cardiac carcinoma tissue samples (P<0.001), but had a non-linear correlation (P=0.575).
CONCLUSION: Abnormal Fas and FasL expressions in cardiac carcinoma and lymph node tissues are involved in carcinogenesis and metastasis of gastric cancer.

Entities:  

Keywords:  Cardiac carcinoma; Fas; Fas ligand FasL; lymph nodes

Mesh:

Substances:

Year:  2015        PMID: 26617948      PMCID: PMC4637764     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

1.  Apoptosis induced by a chimeric Fas/FLICE receptor: lack of requirement for Fas- or FADD-binding proteins.

Authors:  S A Memon; J Hou; M B Moreno; C M Zacharchuk
Journal:  J Immunol       Date:  1998-03-01       Impact factor: 5.422

Review 2.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

3.  Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC).

Authors:  Y Fukuzawa; K Takahashi; K Furuta; T Tagaya; T Ishikawa; K Wada; Y Omoto; T Koji; S Kakumu
Journal:  J Gastroenterol       Date:  2001-10       Impact factor: 7.527

4.  Overexpression of Fas ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the esophagus.

Authors:  M Younes; M R Schwartz; D Finnie; A Younes
Journal:  Hum Pathol       Date:  1999-11       Impact factor: 3.466

5.  Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas.

Authors:  Satoru Kase; Mitsuhiko Osaki; Hironobu Adachi; Nobuaki Kaibara; Hisao Ito
Journal:  Int J Oncol       Date:  2002-02       Impact factor: 5.650

6.  Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines.

Authors:  Kenneth H Shain; Terry H Landowski; William S Dalton
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

7.  Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.

Authors:  Tae-Bum Lee; Young-Don Min; Sung-Chul Lim; Kyung-Jong Kim; Ho-Jong Jeon; Seok-Min Choi; Cheol-Hee Choi
Journal:  J Gastroenterol Hepatol       Date:  2002-01       Impact factor: 4.029

8.  Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes.

Authors:  Kristian Hallermalm; Anna De Geer; Rolf Kiessling; Victor Levitsky; Jelena Levitskaya
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

9.  The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.

Authors:  Yasushi Takahama; Yukishige Yamada; Koji Emoto; Heisuke Fujimoto; Tomoyoshi Takayama; Masatoh Ueno; Hideki Uchida; Shuya Hirao; Takashi Mizuno; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

Review 10.  Recent advances in research on multistage tumorigenesis.

Authors:  A Compagni; G Christofori
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more
  2 in total

Review 1.  Positive and negative functions of B lymphocytes in tumors.

Authors:  Meng Shen; Qian Sun; Jian Wang; Wei Pan; Xiubao Ren
Journal:  Oncotarget       Date:  2016-08-23

Review 2.  Noncoding RNAs: the shot callers in tumor immune escape.

Authors:  Lei Liu; Qin Wang; Zhilin Qiu; Yujuan Kang; Jiena Liu; Shipeng Ning; Yanling Yin; Da Pang; Shouping Xu
Journal:  Signal Transduct Target Ther       Date:  2020-06-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.